Skip to main content

Table 3 Sensitivity and Specificity of the single or multiple methylation markers in the diagnosis of NMIBC

From: Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer

  % Sensitivity (Se) % Specificity (Sp)
Diagnosis set (n =272)
HS3ST2 82.0 (137/167) 21.20 (22/105)
SEPTIN9 90.4 (151/167) 67.6 (71/105)
SLIT2 90.4 (151/167) 18.1 (19/105)
HS3ST2 + SEPTIN9 90.4 (151/167) 72.4 (76/105)
HS3ST2 + SLIT2 90.4 (151/167) 34.3 (36/105)
SEPTIN9 + SLIT2 91.0 (152/167) 71.4 (75/105)
HS3ST2 + SEPTIN9 + SLIT2 90.4 (151/167) 75.2 (79/105)
  1. Note: Performance Se/Sp for either 1/highest Sp with Se > 90 % or 2/highest Sp if no Se > 90 %